ClinicalTrials.gg
Sign In
Not yet recruitingNCT07467798Updated Apr 22, 2026

A Proof-of-concept Study of Ultrasound Stimulation of the Neck to Enhance Anti-shock Efficacy

An interventional study of Low-intensity pulsed ultrasound in Shock, sponsored by Tao Liu. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-22.

Sponsored by Tao Liu · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The objective of this clinical study is to evaluate the initial efficacy and safety of LIPUS as an adjunct to standard therapy in patients with shock. The investigators will invite patients to participate in a proof-of-concept study investigating the efficacy of neck ultrasound stimulation to enhance anti-shock treatment, involving brief exposure to low-intensity pulsed ultrasound. This study examines whether LIPUS can enhance blood pressure in patients with shock, improve the efficacy of antihypotensive treatment, and reduce the dosage and duration of vasoactive drugs during active pharmacological therapy. By applying LIPUS as an adjunct to conventional treatment in clinical cases of shock, we aim to determine the clinical value of LIPUS and establish a theoretical foundation for developing innovative new therapies for shock.

02

Conditions studied

  • Shock

Browse trials for

03

In context

Shock

487 studies on the registry are indexed under Shock; 107 are open to participants now.

This study's planned enrollment of 30 is below the median of 100 across 229 interventional studies indexed under Shock.

Browse Shock studies →

Lead sponsor

Tao Liu is the lead sponsor of 4 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with shock who are ≥18 years of age and have a systolic blood pressure (SBP) between 60 mmHg and 90 mmHg;
  • Patients with arterial blood pressure monitoring or peripheral arterial pressure monitoring with intervals of single-digit minutes;
  • Patients with mild to moderate shock with a shock index (SI) of 1 ≤ SI ≤ 2;
  • Patients with complete medical records.

Exclusion criteria

Exclusion Criteria:

  • Patients with unstable condition and estimated survival time \<24 hours;
  • Patients requiring emergency surgery to achieve control of their condition;
  • Perioperative patients requiring surgery due to conditions other than hypotension;
  • Pregnant or lactating patients;
  • Patients with neck wounds and/or carotid artery plaques who are unsuitable for ultrasound stimulation of the left carotid sinus;
  • Patients deemed unsuitable for inclusion by the investigator.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Experimental group

    Device: Low-intensity pulsed ultrasound

  • No intervention
    Control group

Interventions

  • DeviceLow-intensity pulsed ultrasound

    During periods of stable blood pressure, administer cervical ultrasound stimulation (3-minute stimulation followed by a 2-minute interval, repeated cyclically; total stimulation duration not exceeding 60 minutes).

    Also known as: LIPUS

06

What researchers measure

Primary outcomes

  1. The proportion of patients whose SBP exceeded 90 mmHg and remained stable for at least 5 minutes within 5 minutes of receiving LIPUS treatment or control group treatment

    Time frame: From the start of treatment to 60 minutes after the intervention

Secondary outcomes

  1. The proportion of cases where blood pressure increased by more than 10,15,or 20 mmHg above pre-treatment levels and remained elevated for at least 5 minutes, along with the duration of elevation.

    Time frame: From the start of treatment to 60 minutes after the intervention

  2. The total duration from achieving a blood pressure of ≥90 mmHg after treatment until it stabilizes and subsequently drops back to ≤90 mmHg.

    Time frame: From the start of treatment to 60 minutes after the intervention

  3. Time from initiation of LIPUS therapy to patient's SBP exceeding 90 mmHg

    Time frame: From the start of treatment to 60 minutes after the intervention

  4. Shock Index (SI) Changes

    Time frame: Before treatment and 60 minutes after treatment

  5. Heart Rate Variability (HRV) Changes

    Time frame: Before treatment and 60 minutes after treatment

  6. Drug dosages from the initiation of LIPUS therapy until the patient's SBP reaches the effective target

    Time frame: From the start of treatment to 60 minutes after the intervention

  7. mRS scores for patients in the follow-up control group and experimental group

    Time frame: 3 months

  8. Length of Stay in Intensive Care Unit (ICU)

    Time frame: 3 months

  9. Total hospitalization costs

    Time frame: 3 months

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2026; primary completion for May 2027, 12 months later.

Of 67 non-industry interventional studies with no phase under Shock, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 38. This study's planned 12 months is below that.

Counting every sponsor, half of 70 studies reached it within 25 months; a quarter within 8 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2026
First posted
Mar 12, 2026
StartEst.
May 2026
Primary completionEst.
May 2027
CompletionEst.
Nov 2027
Last update
Apr 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07467798
Lead sponsor
Tao Liu
Collaborators
Tianjin Medical University General Hospital, Xuanwu Hospital, Beijing
Responsible party
Tao Liu (investigator, The George Institute) — Sponsor-investigator
First posted
Mar 12, 2026
Start date
May 2026 (estimated)
Primary completion
May 2027 (estimated)
Completion
Nov 2027 (estimated)
Last update
Apr 22, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Shock →

Other studies from this sponsor

Tao Liu

Start the discussion